Conducting clinical trials during the COVID-19 pandemic-a collaborative trial network response.

Australasia COVID-19 Clinical Trials as Topic Humans Pandemics Research Personnel

Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
14 Apr 2021
Historique:
received: 30 11 2020
accepted: 16 03 2021
entrez: 15 4 2021
pubmed: 16 4 2021
medline: 14 5 2021
Statut: epublish

Résumé

The unprecedented demand placed on healthcare systems from the COVID-19 pandemic has forced a reassessment of clinical trial conduct and feasibility. Consequently, the Australasian Kidney Trials Network (AKTN), an established collaborative research group known for conducting investigator-initiated global clinical trials, had to efficiently respond and adapt to the changing landscape during COVID-19. Key priorities included ensuring patient and staff safety, trial integrity and network sustainability for the kidney care community. New resources have been developed to enable a structured review and contingency plan of trial activities during the pandemic and beyond.

Identifiants

DOI: 10.1186/s13063-021-05200-0 PMID: 33853661 PMC: PMC8045567
pubmed: 33853661
doi: 10.1186/s13063-021-05200-0
pii: 10.1186/s13063-021-05200-0
pmc: PMC8045567
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

278

Subventions

Organisme : National Health and Medical Research Council
ID : APP1092957

Références

Am J Kidney Dis. 2015 Aug;66(2):212-22
pubmed: 25943716
BMC Med Res Methodol. 2020 Aug 12;20(1):208
pubmed: 32787782
Br J Clin Pharmacol. 2015 Apr;79(4):660-8
pubmed: 25327707
Kidney Int. 2014 Jan;85(1):23-30
pubmed: 24088955
Trials. 2020 Sep 5;21(1):765
pubmed: 32891161
NPJ Digit Med. 2020 Jul 31;3:101
pubmed: 32821856
Kidney Int. 2020 Dec;98(6):1549-1558
pubmed: 32853631
Trials. 2018 Feb 23;19(1):139
pubmed: 29475444
Kidney Int. 2020 Dec;98(6):1540-1548
pubmed: 32979369
Kidney Int. 2020 Sep;98(3):572-578
pubmed: 32464216
Kidney Int. 2020 Dec;98(6):1402-1404
pubmed: 33065131
N Engl J Med. 2016 Aug 4;375(5):454-63
pubmed: 27518663
BMJ. 2015 May 08;350:h2147
pubmed: 25956159

Auteurs

Laura Robison (L)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia. l.robison@uq.edu.au.
ORCID: 0000-0002-9043-5942

Yeoungjee Cho (Y)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
The Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.

Andrea K Viecelli (AK)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
The Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.

David W Johnson (DW)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
The Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
The Translational Research Institute, Brisbane, QLD, Australia.

Carmel M Hawley (CM)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
The Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
The Translational Research Institute, Brisbane, QLD, Australia.

Andrea Valks (A)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.

Peta-Anne Paul-Brent (PA)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.

Ruth Stastny (R)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.

Julie Varghese (J)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.

Charani Kiriwandeniya (C)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.

Elaine M Pascoe (EM)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.

Liza A Vergara (LA)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.

Magid A Fahim (MA)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
The Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Metro North Hospital & Health Service, Brisbane, QLD, Australia.

Neil Boudville (N)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
The Medical School, University of Western Australia, Perth, WA, Australia.

Rathika Krishnasamy (R)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Department of Nephrology, Sunshine Coast University Hospital, Birtinya, QLD, Australia.

Donna Reidlinger (D)

Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Régions géographiques › Océanie › Australasie › Conducting clinical trials during the COVID-19...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Conducting clinical trials during the COVID-19...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Conducting clinical trials during the COVID-19...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Conducting clinical trials during the COVID-19...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Épidémies de maladies › Épidémies › Pandémies › Conducting clinical trials during the COVID-19...
questionsmedicales.fr › Personnes › Groupes professionnels › Personnel de recherche › Conducting clinical trials during the COVID-19...